Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14385862 | 0.88 | MAPT (0.33) | MAPTRAB9AMAPK1TDP1L3MBTL1 | |
| SCHEMBL14385481 | 0.82 | TBXAS1 (0.39) | MAPK1MEN1KMT2A | |
| SCHEMBL13717023 | 0.78 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL14080254 | 0.76 | — | — | |
| SCHEMBL13717219 | 0.74 | TBXAS1 (0.33) | MAPK1MEN1KMT2A | |
| SCHEMBL14385471 | 0.64 | MEN1 (0.34) | MAPTRAB9AMAPK1TDP1MEN1 | |
| SCHEMBL5495804 | 0.64 | MEN1 (0.33) | MAPTRAB9AMAPK1TDP1MEN1 | |
| SCHEMBL13717110 | 0.63 | MAPT (0.33) | MAPTRAB9AMAPK1TDP1MEN1 | |
| SCHEMBL18074365 | 0.62 | MEN1 (0.34) | MAPTRAB9AMAPK1TDP1MEN1 | |
| SCHEMBL14366669 | 0.62 | MEN1 (0.42) | MAPTRAB9AMAPK1TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569079-B2 | Polycationic monochromophoric hydrazone compounds, dye compositions comprising such polycationic compounds and dyeing process using them | L'OREAL S.A. (FR) | 2009-08-04 | — | — | US | disclosed |
| US-20080263785-A1 | Polycationic monochromophoric hydrazone compounds, dye compositions comprising such polycationic compounds and dyeing process using them | L'OREAL S.A. (FR) | 2008-10-30 | — | — | US | disclosed |
| WO-2007122340-A1 | CATIONIC DICHROMOPHORIC COMPOUND CONTAINING TWO UNITS OF HYDRAZONE TYPE AND COMPRISING A CATIONIC LINKER ARM, DYE COMPOSITION COMPRISING AT LEAST ONE SUCH COMPOUND, METHOD FOR THE USE THEREOF AND USES | L'ORÉAL (FR) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080263785-A1 | Polycationic monochromophoric hydrazone compounds, dye compositions comprising such polycationic compounds and dyeing process using them | KRT18, CKMT1A; CKMT1B, XRCC5 | MAPT 1719/4885RAB9A 4310/4885MAPK1 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.